中国临床药学杂志

目的 探究氟桂利嗪联合倍他司汀对梅尼埃病（MD）的疗效和安全性。方法 选取2021年12月至2023年12月就诊的梅尼埃病病例98例，随机分为对照组和研究组，每组49例。对照组予倍他司汀治疗，研究组予氟桂利嗪联合倍他司汀治疗，2组均连续治疗21 d。比较2组治疗后的疗效、临床症状改善情况、红细胞聚集指数、全血黏度、红细胞压积、眩晕障碍量表（DHI）评分、平均听阈、耳鸣程度和不良反应发生情况。结果 研究组的治疗总有效率高于对照组（P<0.05）。治疗后2组眩晕每周发作频率、每次发作持续时间、DHI评分、红细胞聚集指数、全血黏度、红细胞压积、平均听阈和耳鸣程度均低于治疗前（P<0.05），并且研究组低于对照组（P<0.05）。2组不良反应总发生率比较差异无统计学意义（P> 0.05）。结论 氟桂利嗪联合倍他司汀能够改善MD患者临床症状、血液流变学指标和听力状况，疗效优于单用倍他司汀，并且安全性良好，值得临床推广。

AIM To investigate the clinical efficacy and safety of flunarizine hydrochloride capsules combined with betaustine hydrochloride on Meniere's disease(MD). METHODS A total of 98 patients diagnosed with Meniere's disease from December 2021 to December 2023 were selected and randomly divided into control group and trial group, with 49 patients in each group. The control group was treated with betahistine hydrochloride, while the trial group was treated with flunarizine hydrochloride capsules combined with betamethasone hydrochloride. Both groups were treated continuously for 21 days. The clinical efficacy, improvement of dizziness symptoms, hemorheological indicators(erythrocyte aggregation index, whole blood viscosity, and hematocrit), dizziness handicap inventory(DHI) scores, mean hearing threshold, degree of tinnitus, and adverse reactions of 2 groups were observed after treatment. RESULTS After 21 days of treatment,the total effective rate of the trial group was 91.84%, which was higher than the control group's 71.43%(P < 0.05). The disappearance time of dizziness, seizure frequency, seizure duration, and DHI scores decreased after treatment, with the trial group showing significantly lower values than the control group(P < 0.05). The erythrocyte aggregation index,whole blood viscosity, hematocrit, mean hearing threshold, and tinnitus improved post-treatment, and these measures were significantly better in the trial group compared to the control group(P < 0.05). CONCLUSION Flunarizine hydrochloride capsule combined with betaustine hydrochloride can improve clinical symptoms and hemorheological indices in Meniere's disease(MD) patients, enhance hearing, and exhibits a better therapeutic effect than betahistine alone. Furthermore, the combination regimen demonstrates good safety and is worthy of clinical recommendation.